PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 14961065-5 2004 Inducible nitric oxygen synthase gene expression, nitric oxide production, as well as TNFalpha secretion were enhanced by PA or DFX as the sole stimuli. Deferoxamine 128-131 tumor necrosis factor Mus musculus 86-94 2745981-6 1989 Pretreatment with the iron chelator, desferal, or the free radical scavenger, BHA, inhibited TNF release in these animals. Deferoxamine 37-45 tumor necrosis factor Mus musculus 93-96 10988358-2 2000 In vivo studies demonstrated that pretreatment of mice with DFX reduces tumor necrosis factor alpha (TNF-alpha) serum levels and increases the rate of survival of mice inoculated with lethal doses of lipopolysaccharide (LPS) or Escherichia coli O111:B4. Deferoxamine 60-63 tumor necrosis factor Mus musculus 72-99 10988358-2 2000 In vivo studies demonstrated that pretreatment of mice with DFX reduces tumor necrosis factor alpha (TNF-alpha) serum levels and increases the rate of survival of mice inoculated with lethal doses of lipopolysaccharide (LPS) or Escherichia coli O111:B4. Deferoxamine 60-63 tumor necrosis factor Mus musculus 101-110 10988358-4 2000 On the other hand, DFX prevents mortality induced either by LPS or murine recombinant TNF-alpha in D(+)-galactosamine (GalN)-sensitized mice. Deferoxamine 19-22 tumor necrosis factor Mus musculus 86-95 10988358-5 2000 These protective actions of DFX correlate with an attenuated tissue damage observed in lungs, livers and kidneys of LPS-treated animals and GalN-sensitized mice inoculated with TNF-alpha. Deferoxamine 28-31 tumor necrosis factor Mus musculus 177-186 7622893-4 1995 DFO B inhibited interleukin (IL)-6, IL-12, and tumor necrosis factor (TNF)-alpha mRNA production 4-fold (shown by semiquantitative reverse transcription polymerase chain reaction). Deferoxamine 0-3 tumor necrosis factor Mus musculus 47-80 7622893-5 1995 TNF-alpha and IL-6 protein production was reduced 50% by DFO B. Deferoxamine 57-60 tumor necrosis factor Mus musculus 0-9 7790027-4 1995 Deferoxamine (a ferric iron chelator) and dithiothreitol (a sulfhydryl reagent) both prevented DNA damage and cell killing, indicate that hydroxyl radicals generated from O2- and H2O2 produced by the mitochondria in a process catalysed by iron contributed to DNA damage and that this pathway may be involved in TNF-alpha-induced cytotoxicity. Deferoxamine 0-12 tumor necrosis factor Mus musculus 311-320 1550349-10 1992 The antioxidants mannitol and benzoate, as well as the iron chelator deferoxamine, reduced the extent of TNF alpha-induced oxidant effects in hepatocytes, which indicates that the oxidant stress may involve hydroxyl radical generation. Deferoxamine 69-81 tumor necrosis factor Mus musculus 105-114 10569191-6 1999 Pretreatment of the cells with catalase (H2O2 scavenger) or deferoxamine (*OH scavenger) effectively inhibits NF-kappaB and TNFalpha activation, whereas superoxide dismutase (O2 scavenger) has an opposite effect. Deferoxamine 60-72 tumor necrosis factor Mus musculus 124-132 8324080-4 1993 The iron chelator deferoxamine was able to protect against TNF cytotoxicity in L929 cells. Deferoxamine 18-30 tumor necrosis factor Mus musculus 59-62 2745981-7 1989 Less TNF was also detected in mice given desferal before LPS in the absence of exogenous radical generator. Deferoxamine 41-49 tumor necrosis factor Mus musculus 5-8 26277391-4 2015 Furthermore, the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), nitric oxide (NO) and prostaglandin E2 (PGE2) induced by LPS was inhibited by DFO in RAW264.7 macrophages. Deferoxamine 180-183 tumor necrosis factor Mus musculus 31-58 29678877-7 2018 DFO significantly improved vital parameters of adipose tissue biology by reducing reactive oxygen species and inflammatory marker (TNFalpha, IL-2, IL-6, and Hepcidin) secretion, by increasing the levels of antioxidant enzymes, hypoxia-inducible factor-1alpha (HIF-1alpha) and HIF-1alpha-targeted proteins, and by altering adipocytic iron-, glucose- and lipid-associated metabolism proteins. Deferoxamine 0-3 tumor necrosis factor Mus musculus 131-139 25361473-6 2015 Treatment with NAC, DFX, or NAC plus DFX significantly decreased H2O2 production (24, 58, and 72%, respectively), and levels of 4-HNE-protein adducts (62, 33, and 71%, respectively), TNF-alpha (32, 29, and 31%, respectively), and NF-kappaB (34, 38, and 52%, respectively) on dystrophic muscle cells. Deferoxamine 20-23 tumor necrosis factor Mus musculus 183-192 25361473-6 2015 Treatment with NAC, DFX, or NAC plus DFX significantly decreased H2O2 production (24, 58, and 72%, respectively), and levels of 4-HNE-protein adducts (62, 33, and 71%, respectively), TNF-alpha (32, 29, and 31%, respectively), and NF-kappaB (34, 38, and 52%, respectively) on dystrophic muscle cells. Deferoxamine 37-40 tumor necrosis factor Mus musculus 183-192 18025230-4 2007 Basal and TNF-induced expression of VCAM-1, ICAM-1, and E-selectin were increased in Hmox1(-/-) vs Hmox1(+/+) EC, an effect reversed by Fe chelation using deferoxamine mesylate (DFO). Deferoxamine 155-176 tumor necrosis factor Mus musculus 10-13 25644393-10 2015 DFO prevented LPS-induced microglial activation and elevations of IL-1beta and TNF-alpha levels in the hippocampus. Deferoxamine 0-3 tumor necrosis factor Mus musculus 79-88 18025230-4 2007 Basal and TNF-induced expression of VCAM-1, ICAM-1, and E-selectin were increased in Hmox1(-/-) vs Hmox1(+/+) EC, an effect reversed by Fe chelation using deferoxamine mesylate (DFO). Deferoxamine 178-181 tumor necrosis factor Mus musculus 10-13 17883261-7 2007 Noncytotoxic concentrations of subway PM (but not CB, TiO2, or DEPs) induced a time- and dose-dependent increase in TNFalpha and MIP-2 production by RAW 264.7 cells, in a manner involving, at least in part, PM iron content (34% inhibition of TNF production 8 h after stimulation of RAW 264.7 cells with 10 microg/cm2 RER particles pretreated with deferoxamine). Deferoxamine 347-359 tumor necrosis factor Mus musculus 116-124